Gland Pharma Ltd (GLAND) — Announcement | 31 August 2026

· BSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Gland Pharma schedules September 2026 investor meetings
💡 Investor Takeaway
Investors can engage directly with management during scheduled meetings.

Gland Pharma announced its schedule of analyst and institutional investor meetings for September 2026, including one-on-one sessions with Carnelian Capital, First Ray Capital, and Jefferies, as well as group meetings at the BofA Asia Pacific Conference and with JP Morgan. The company also disclosed details of its registered office and compliance contacts. These meetings provide investors with direct engagement opportunities with management and key institutional stakeholders.

📄 View Original Announcement (PDF)

About Gland Pharma Ltd (GLAND)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹47,316.21 Cr P/E: 41.9 ROE: 10.9% ROCE: 15.2% Div Yield: 0.70%

View full GLAND stock details →

📡 Get AI alerts when GLAND files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLAND — Free

📊 More GLAND filings

See all GLAND filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLAND files new disclosures

Track GLAND filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GLAND — Free

Free account · 2 AI queries/day